ArticleInternational journal of clinical and experimental pathology2019
SGK1 protein expression is a prognostic factor of lung adenocarcinoma that regulates cell proliferation and survival.
Article in International journal of clinical and experimental pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 6 citations in OpenAlex.
- Unraveling the Potential of SGK1 in Osteoporosis: From Molecular Mechanisms to Therapeutic Targets.Biomolecules · 2025Review
- Serum/glucocorticoid-regulated kinase 1 contributes to the proliferation of varicella-zoster virus and induction of cyclin B1 expression.Archives of virology · 2024Article
- Modeling of senescence-related chemoresistance in ovarian cancer using data analysis and patient-derived organoids.Frontiers in oncology · 2023Article
- Discovery of a novel Aurora B inhibitor GSK650394 with potent anticancer and anti-Journal of enzyme inhibition and medicinal chemistry · 2022Article
- Integrated spatial analysis of gene mutation and gene expression for understanding tumor diversity in formalin-fixed paraffin-embedded lung adenocarcinoma.Frontiers in oncology · 2022Article
- Serum and Glucocorticoid-Inducible Kinase 1 (SGK1) in NSCLC Therapy.Pharmaceuticals (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The etiological or clinicopathological significance of serum glucocorticoid-induced protein kinase 1 (SGK1) in lung adenocarcinoma remains unclear. This study aimed to investigate the role of SGK1 in the development and progression of human lung adenocarcinoma and the effects of targeted inhibition of intrinsic SGK1 expression on the proliferation of lung adenocarcinoma cells. SGK1 protein expression in 150 human cases of lung adenocarcinoma was detected by immunohistochemical analysis, and the relationships between SGK1 expression and clinicopathological features were assessed. In addition, endogenous SGK1 profiles were determined in seven lung adenocarcinoma cell lines. Cell proliferation, cell cycle distribution, and apoptosis were characterized in the absence and presence of SGK1 inhibitors. Compared to the adjacent normal tissues, significantly higher SGK1 expression levels were detected in the cytoplasm in cancerous lung adenocarcinoma tissues. Besides, SGK1 expression correlated with lymph node metastasis, distant metastasis, and pathological staging. Univariate analysis suggested that overexpression of this protein correlated significantly with a poor prognosis. Cultured lung adenocarcinoma cells expressed relatively high SGK1 levels, and inhibition of this protein was associated with G2 cell cycle arrest and reduced cyclin B1 and cdc2 expression. Pharmacological SGK1 inhibition experiments corroborated the role of this protein in cell cycle progression. SGK1 expression correlated closely with lung adenocarcinoma progression and could be used as a prognostic marker. Endogenous SGK1 inhibition abrogated lung adenocarcinoma cell proliferation via G2/M-phase cell cycle arrest, which was likely mediated by the concerted actions of cell cycle regulators.
Indexed as
Identifiers
31933845PMC6945076W3002208636What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.